04/23/2026 08:00
Pantheon Expands Global Private Wealth Platform with Infrastructure Secondaries Fund Launch

Pantheon, a leading global private markets investor, today announced the regulatory approval for the Pantheon Global Infrastructure Secondaries Fund (“PGIS”). Domiciled in Luxembourg, the evergreen fund represents a significant milestone in Pantheon’s private wealth strategy and the expansion of the firm’s evergreen offering. The launch of PGIS now cements Pantheon’s global evergreen offerings across private equity, private credit secondaries, and infrastructure secondaries and complements its ...

04/23/2026 08:00
Demand for GP Financing Is Rising, but the Managers Who Need It Most Are Finding It Hardest to Access

Corpay Private Markets, formerly Alpha Private Markets, today publishes the fourth edition of its Lender Book Report, focusing on GP financing across private markets. While demand for GP-level liquidity is rising – driven by longer fundraising cycles, slower exit activity, and increasing GP commitment requirements – access to financing is not expanding evenly. That is the central finding of the latest Lender Book Report. Unlike most research in the fund finance sector, which draws on surveys ...

04/23/2026 10:10
Chiesi Reports Strong FY2025 Financial and Sustainability Results and Announces Leadership Transition Highlights

Chiesi Group (“Chiesi”), an international research‑focused biopharmaceutical company and certified B Corp, today announced its financial results for the year ended 31 December 2025. Chiesi reported €3.625 billion in consolidated revenues, an increase of 8.2% at constant exchange rates (CER) compared to 2024. EBITDA reached €931 million (25.7%). Chiesi closed 2025 with a positive Net Financial Position (cash minus financial liabilities including leasing) of €729 million, improving by €194 mi...

04/23/2026 10:05
REPLY S.p.A.: Shareholders’ Meeting Approves the 2025 Financial Statements

The General Shareholders’ meeting of Reply S.p.A. [EXM, STAR: REY] held today approved the Financial Statements for the financial year 2025, confirming the distribution of a gross dividend of €1.35 per share. The dividend will be paid on 20 May 2026, with dividend date set on 18 May 2026 (record date on 19 May 2026). Approval of the 2025 financial statements The Reply Group closed the 2025 financial year with a consolidated turnover of €2,483.6 million, recording a 8.0% increase compared ...

04/23/2026 11:00
OG&E to Host Bidgely EmPOWER AI 2026 Annual Conference in New York City

Bidgely's premier energy intelligence conference, EmPOWER AI, will be held May 12-14 in New York City to unite utility leaders, energy researchers and technology experts around artificial intelligence (AI) in the energy sector. Hosted by OG&E with sessions led by Alabama Power, Eversource, NV Energy, PSEG Long Island, Xcel Energy and more, EmPOWER AI 2026 will highlight how utilities are moving beyond AI experimentation toward enterprise-wide scalability. This press release features multim...

04/23/2026 11:13
Croma Pharma Launches AI-Driven Tech Venture to Revolutionize Aesthetic Medicine via Clinicore Platform

Croma Pharma has launched a strategic joint venture to accelerate the development of Clinicore, its premium digital solution for aesthetic practices. This dedicated entity will focus on scaling the next generation of the platform while ensuring full continuity for existing users. Clinicore: Elevating Practice Excellence through AI Clinicore is a specialized SaaS (Software as a Service) solution designed to optimize the daily operations of aesthetic clinics. By automating patient management,...

04/23/2026 11:00
NIQ Launches Commerce Lab to Build the Data and Measurement Layer for AI-Driven Commerce

NielsenIQ (NYSE: NIQ) today announced the launch of NIQ Commerce Lab, where the company is building the technology infrastructure for AI-driven commerce. The Lab will develop the data platforms, APIs, and measurement systems that power how products are discovered, evaluated, and purchased in AI-mediated environments. This includes what the industry often refers to as agentic commerce, but extends across quick commerce, social commerce, and other emerging channels—where AI is becoming the comm...

04/23/2026 12:00
Brev Raises $3.3 Million to Build the AI-Native Layer Between Business Goals and Work

Brev, the AI-native layer between business goals and work, today announced it has raised $3.3 million in pre-seed funding led by Resolute Ventures, with participation from shuckerVC, Duro VC, Gaingels, and FOG Ventures. The company will use the funding to accelerate product development, deepen integrations, and grow its engineering team as demand rises for software that gives leaders real-time visibility into execution across the business. This press release features multimedia. View the full ...

04/23/2026 12:00
Philip Morris International Expands its Partnership with Ducati Corse as Decades-Long Partnership Races Forward with Purpose

Philip Morris International1 (NYSE: PM) today announced an expanded partnership with Ducati Corse for the 2026 season and beyond. This next chapter introduces a major development: the ZYN brand of nicotine pouches—the number one nicotine pouch brand globally2—will feature on Ducati Corse MotoGP liveries at select races throughout the seasons. Just as Ducati pushes the limits of performance, ZYN represents PMI’s commitment to delivering innovation, offering a product that delivers exceptional ...

04/23/2026 11:29
GE HealthCare Announces First Patient Dosed in Phase 2/3 LUMINA Trial for Manganese-Based MRI Contrast Agent Under FDA Fast Track Designation, Further Advancing Its Innovation Pipeline of Novel Imaging Agents

GE HealthCare (Nasdaq: GEHC) today announced the first patient has been dosed in the international, multi-center Phase 2/3 LUMINA clinical trial of its manganese-based magnetic resonance imaging (MRI) contrast agent, mangaciclanol, at Mayo Clinic in Rochester, Minnesota. Mangaciclanol, if approved, could offer an alternative to – or even replace – gadolinium-based MRI contrast agents, the current standard of care. The investigational agent has been granted Fast Track designation by the U.S. Foo...